Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
108.24
(
0.71%
)
Bitcoin
77,105.98
(
-0.39%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 222126

Saturday, 11/10/2018 4:04:56 PM

Saturday, November 10, 2018 4:04:56 PM

Post# of 257580

NKTR—…melanoma and RCC are not right indications to test PD-L1- conversion to PD-L1+ theory based on small-n single arm trial because PD1/PD-L1 are doing quite well as monotherapy in this population.

True, but people still want to see the “conversion” data anyhow.

Inasmuch as the NKTR-214/Opdivo program in NSCLC looks iffy, it’s unclear to me which phase-3 indications for NKTR-214/Opdivo will be the best ones for testing the PD-L1-conversion hypothesis.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today